Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lixudebart (ALE.F02) / Alentis Therap
RENAL-F02, NCT06047171: Rescue of Nephrons With ALE.F02	Recruiting	2	80	Europe, RoW	ALE.F02, Rituximab, GlucoCorticoid, Cyclophosphamid, Placebo, Immunosuppressive Agents	Alentis Therapeutics AG	Glomerulonephritis Rapidly Progressive	09/25	09/25
FEGATO-01, NCT05939947: A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis	Recruiting	1	38	Europe, US	ALE.F02, Placebo	Alentis Therapeutics AG	Advanced Liver Fibrosis, Liver Cirrhosis	11/24	11/24